Charles Pollack, M.D.
Thrombosis and Antithrombotic Therapy
The term “thrombosis” can refer to both physiological and pathological processes. Thrombosis is a key component of hemostasis in hemorrhage (traumatic or spontaneous), but it is also a source of downstream ischemia and thromboembolism in such conditions as acute coronary syndrome, ischemic stroke, deep venous thrombosis, and pulmonary embolism. Hemostasis is a complex, delicate and easily perturbed component of overall homeostasis. It may be disturbed by inherited causes (such as hemophilia or Factor V Leiden thrombophilia), by diverse acquired diseases (such as atherosclerosis and subsequent plaque rupture, and liver disease, and DIC), by acute injury (such as multisystem trauma with hemorrhagic shock and coagulopathy, or by the erosion of a colonic neoplasm into a blood vessel), or by iatrogenic intervention, primarily with the therapeutic use of anticoagulant and antiplatelet agents.
This page is a living resource for new and exciting developments in thrombosis and antithrombotic therapy. We will primarily focus on pharmacological interventions that drive hemostasis in one direction of another—stopping bleeding, preventing pathologic thrombosis, and reversing the action of various antithrombotic agents. Please feel free to submit entries both to catch us up and to keep us current. This is a multidisciplinary, truly interprofessional issue.
Questions or Comments about Thrombosis?